Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Birinapant and Carboplatin for Recurrent High Grade Serous Ovarian Cancer
NCT02756130Phase 2Withdrawn
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Aug 2018
- Primary completion
- Feb 2020
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of birinapant in Ovarian adenocarcinoma, serous, Serous adenocarcinoma of the fallopian tube (PFTC), primary peritoneal carcinoma (PPC), sponsored by UCLA Jonsson Comprehensive Cancer Center. Planned start Aug 2018; status: withdrawn.
02
Drugs
birinapant
03
Conditions
Ovarian adenocarcinoma, serousSerous adenocarcinoma of the fallopian tube (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT02756130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02756130.